Total Humeral Endoprosthetic Replacement following Excision of Malignant Bone Tumors

Table 1

Demographics and surgical details.

Case	Gender	Age; (yrs)	Diagnosis	Previous treatment	Plastic surgery	Ulna stem	EBL; (mL)	DOS; (min)	LOS; (days)
Primary
1	M	67	Unclassified	Cx	IR + LDMF	Long	850	347	13
2	F	11	OS-osteoblastic	Cx	ER + LDMF	Short	800	314	7
3	M	38	CS	Cx	ER + LDMF	Long	600	325	8
4	F	12	OS	Cx	ER + LDMF	Short	1075	301	5
5	F	70	OS-high-grade surface	Cx, IM nail	IR	Short	500	345	5
6	F	13	ES	Cx	IR	Long	1150	165	4
7	F	32	OS-fibroblastic	Cx, IM nail	ER + LDMF	Short	400	180	8
8	F	4	OS-osteoblastic	Cx	ER	Short	100	57	4
9	M	16	OS-telangiectatic	Cx	IR	Long	550	362	3
10	M	9	OS-high-grade surface	Cx	IR	Short	250	339	8
11	F	24	OS chondroblastic	Cx	IR + LDMF	Long	1000	469	9
Metastatic
12	F	46	Breast		IR	Short	4000	210	10
13	M	57	Thyroid		IR	Long	1800	271	7
14	M	69	RCC		IR	Long	1000	266	7
15	M	59	RCC	IM nail	IR	Short	350	182	3
16	M	62	RCC	IM nail	IR	Long	400	653	9
17	M	65	RCC		IR	Short	6050	351	5
18	M	66	RCC		IR	Long	900	394	2
19	F	36	ASPS		IR	Long	600	513	31
20	F	62	RCC	Endoprosthesis (prox. humeral)	IR	Long	250	237	14